ABCL News and Press, AbCellera Biologics Inc. From 01/06/23

Summary Baker Brothers’ 13F portfolio value decreased from $17.63B to $15.27B this quarter. Rhythm Pharma and Akero Therapeutics were increased while decreasing argenx SE and Horizon Therapeutics. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they a...

Summary In this article, I will provide my valuation model for AbCellera, building on an article I wrote over a year ago. In the last year, many of my inputs I previously used have changed, given the greater transparency of the company throughout 2022. Some for the better, some for the ...

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time). A live audio webcast of the presentation may be accessed through a ...

Summary While others flock to safety, should you do the opposite? Some of the best times to invest in highly speculative names are when no one wants them, as long as the reasons are macro and not company or industry specific. Now that the tax loss bloodbath is over, here are some po...

AbCellera (Nasdaq: ABCL) announced today that it has entered into a multi-year, multi-target strategic collaboration with AbbVie Inc. (NYSE: ABBV). The partnership will leverage AbCellera’s antibody discovery and development engine to deliver optimized development candidates for up t...

Premium content from Motley Fool Stock Advisor Canada “Best Buys Now” Pick #1: AbCellera ( NASDAQ:ABCL ) AbCellera Biologics ( NASDAQ:ABCL ) develops antibodies to treat infectious diseases. Its AI-powered technology decodes and analyze...

AbCellera (Nasdaq: ABCL) and Rallybio Corporation (Nasdaq: RLYB) announced today that they have entered into a strategic alliance to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. This multi-year, multi-target collaboration will combine AbCellera&#...

Truist has initiated AbCellera Biologics ( NASDAQ: ABCL ) with a buy citing the company's platform that allows for the rapid discovery of antibodies. The firm has a price target of $29 per share (100% upside based on Tuesday's close). Analyst Robyn Karnauskas said that...

Expanded characterization of CD3-binding antibodies includes identification of antibodies that bind regions of CD3 that are distinct from commonly used molecules Robust proof-of-concept study demonstrates T-cell engagers that potently eliminate cancer cells with minimal cyto...

Summary AbCellera reported its Q3 earnings on November 8th, solidly beating estimates on both the top and bottom lines. The company, in the days before the release, indicated that Regeneron has advanced its first GCPR target into preclinical development, further validating its pla...